Curmeric- Nasal-Safety-Efficacy- Community-Quarantine -COVID-19

Safety and efficacy study of the natural product Curmeric-nasal in a quarantined community of primary care due to possible cases of COVID-19.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

RPCEC

Registry ID

RPCEC00000352

Enrollment

148

Registered

2021-01-22

Start date

2020-10-21

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 COVID-19 SARS-CoV2

Interventions

Group I, Curmeric. Natural product that contains extracts of Curcuma longa -in intellectual property process- (nasal) 2 nasal drops in each nostril 3 times a day for 1 month. The group I included, th

Turmeric

Plant Extracts

Administration, Intranasal

Nasal Sprays

Eligibility

Sex/Gender

All

Age

5 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inhabitants of the area in quarantine because of COVID-19 in primary health care.

Exclusion criteria

Exclusion criteria: Known allergy to Turmeric.

Design outcomes

Primary

Measure	Time frame
Number of positive cases for COVID-19 (Number of positive subjects). Measurement time: A month after inclusion	—

Secondary

Measure	Time frame
Adverse Events-AE (Occurrence of AE (Yes, No); Type of event (name of AE); Intensity of AE (light, Moderate, Severe); Outcome (Recovered, Not recovered, Recovered with sequelae, Fatal); Requires treatment (Yes/No)). Measurement time: A month after inclusion	—

Countries

Cuba

Contacts

Public ContactTania Valdes Gonzalez

Center for Technological Applications and Nuclear Development (CEADEN)

taniajapon@gmail.com

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Apr 4, 2026